Exclusive: Alzheimer's group may scrap early look at highly sought Lilly data

Shares of Lilly have jumped 7 percent this week, largely on Wall Street expectations that favorable long-term effectiveness data could emerge from the study of solanezumab, an injectable drug with potential to become the first approved treatment to delay progression of Alzheimer's. A spokesman for the Alzheimer's Association told Reuters on Thursday that the abstracts, summaries of clinical trial data to be presented at the meeting, could be posted within a few days on a special website for those registered for the event.

Exclusive: Alzheimer's group may scrap early look at highly sought Lilly data source: http://finance.yahoo.com/news/exclusive-alzheimers-group-may-scrap-185612061.html